BIM
115.2
+1.5%↑
SRT3
228.5
-0.65%↓
GXI
55.15
+2.89%↑
ICAD
20.98
-1.04%↓
BIM
115.2
+1.5%↑
SRT3
228.5
-0.65%↓
GXI
55.15
+2.89%↑
ICAD
20.98
-1.04%↓
BIM
115.2
+1.5%↑
SRT3
228.5
-0.65%↓
GXI
55.15
+2.89%↑
ICAD
20.98
-1.04%↓
BIM
115.2
+1.5%↑
SRT3
228.5
-0.65%↓
GXI
55.15
+2.89%↑
ICAD
20.98
-1.04%↓
BIM
115.2
+1.5%↑
SRT3
228.5
-0.65%↓
GXI
55.15
+2.89%↑
ICAD
20.98
-1.04%↓
24h
Praegune
Min
118.85
Max
122.35
Sissetulek | -142M 667M |
---|---|
Müük | 152M 5.4B |
P/E Sektori keskmine | 26.27 57.333 |
Aktsiakasum | 2.2 |
Dividenditootlus | 1.34 |
Kasumimarginaal | 12.311 |
EBITDA | 85M 1.6B |
Soovitused | Osta |
---|---|
12 kuu keskmine prognoos | +37.85% upside |
Dividenditootlus Sektori keskmine | 1.34% 2.63% |
---|---|
Järgmine tulemuste avaldamine | 15. mai 2025 |
Turukapital | 33B 98B |
---|---|
Eelmine avamishind | 120.3 |
Eelmine sulgemishind | 120.8 |
By Trading Central
Kindlus
Very Strong Bullish Evidence
117.55 / N/A Toetus ja vastupanu
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
6. märts 2025, 06:27 UTC
Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results
DJ
Loe
11. veebr 2025, 07:03 UTC
Germany's Merck in Talks to Buy SpringWorks Therapeutics
DJ
Loe
10. veebr 2025, 16:38 UTC
SpringWorks Therapeutics Shares Rise on Report it May be Acquired
DJ
Loe
24. apr 2025, 22:51 UTC
Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update
DJ
Loe
24. apr 2025, 20:54 UTC
Merck KGaA: No Final Decision Has Been Taken; No Legally Binding Agreement Has Been Entered Into
DJ
Loe
24. apr 2025, 20:50 UTC
Merck KGaA Confirms Late-Stage Discussions With SpringWorks Therapeutics on Potential Acquisition for About 47c a Share
DJ
Loe
24. apr 2025, 19:05 UTC
Merck KGaA Expected to Pay Close to $47 a Share for SpringWorks, Sources Say -- WSJ
DJ
Loe
24. apr 2025, 19:05 UTC
Merck KGaA, SpringWorks Deal Expected to Be Finalized as Soon as Monday, Sources Say -- WSJ
DJ
Loe
24. apr 2025, 19:05 UTC
Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- WSJ
DJ
Loe
24. apr 2025, 19:05 UTC
Merck KGaA Nears Roughly $3.5 Billion Takeover of SpringWorks Therapeutics, Sources Say -- WSJ
DJ
Loe
6. märts 2025, 11:18 UTC
Impact from U.S. Tariffs Is Manageable for Merck KGaA, CEO Says -- Market Talk
DJ
Loe
6. märts 2025, 11:14 UTC
Merck KGaA's Outlook Signals Greater Transparency -- Market Talk
DJ
Loe
6. märts 2025, 08:20 UTC
Merck KGaA's Earnings Guidance Seems Soft Amid Semiconductor Uncertainty -- Market Talk
DJ
Loe
6. märts 2025, 06:00 UTC
Merck KGaA Expects 2025 Net Sales Between EUR21.5B and EUR22.9B
DJ
Loe
6. märts 2025, 06:00 UTC
Merck KGaA 2024 Adj EPS EUR8.63
DJ
Loe
6. märts 2025, 06:00 UTC
Merck KGaA Expects 2025 EBITDA Before One-Time Items Between EUR6.1B and EUR6.6B
DJ
Loe
6. märts 2025, 06:00 UTC
Merck KGaA 2024 EBIT EUR3.645B
DJ
Loe
6. märts 2025, 06:00 UTC
Merck KGaA 2024 After-Tax Profit EUR2.79B
DJ
Loe
6. märts 2025, 06:00 UTC
Merck KGaA 2024 Ebitda Before One-Time Items EUR6.07B
DJ
Loe
6. märts 2025, 06:00 UTC
Merck KGaA 2024 EBITDA EUR5.78B
DJ
Loe
6. märts 2025, 06:00 UTC
Merck KGaA 2024 Sales EUR21.16B
DJ
Loe
6. märts 2025, 06:00 UTC
Merck KGaA Keeps Dividend at EUR2.20
DJ
Loe
6. märts 2025, 06:00 UTC
Analysts Saw Merck KGaA 2024 Sales at EUR21.14B
DJ
Loe
6. märts 2025, 06:00 UTC
Analysts Saw Merck KGaA 2024 Ebitda Before One-Time Items at EUR6.08B
DJ
Loe
11. veebr 2025, 16:45 UTC
Merck's Potential Springworks Deal Unlikely to Move Needle on Earnings -- Market Talk
DJ
Loe
11. veebr 2025, 10:54 UTC
Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk
DJ
Loe
11. veebr 2025, 10:52 UTC
German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk
DJ
Loe
6. jaan 2025, 13:08 UTC
Merck KGaA: Transaction closed on Dec. 23, 2024
DJ
Loe
6. jaan 2025, 13:07 UTC
Merck KGaA: Didn't Disclose Financial Details
DJ
Loe
6. jaan 2025, 13:06 UTC
Merck KGaA: HUB's Organoid Offering Complements Merck KGaA's Cell Culture Portfolio
DJ
Loe
Hinnamuutus
By TipRanks
12 kuu keskmine prognoos
Keskmine 166.25 EUR 37.85%
Kõrge 190 EUR
Madal 107 EUR
Põhineb 9 Wall Streeti analüütiku instrumendi Merck KGaA 12 kuu hinnasihil - viimase 3 kuu andmed.
By TipRanks
Osta
9 ratings
6
Osta
2
Hoia
1
Müü
Põhineb 9 analüütiku instrumendi Merck KGaA aktsia reitingul - viimase 3 kuu andmed.
By Trading Central
Lühikene perspektiiv
Very Strong Bullish Evidence
Recent bullish events outweigh bearish events.
Keskpikk perspektiiv
Bearish Evidence
All events are bearish.
Pikk perspektiiv
Bearish Evidence
All events are bearish.
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$